Immunophotonics

Focus: Immunophotonics is a public biotechnology company headquartered in St. Louis focused on developing autologous cancer vaccines, primarily targeting oncology indications.

Oncology Infectious Diseases Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Immunophotonics

AI assessmentNot Hiring

No open roles listed right now. Follow Immunophotonics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

1.0% IP-001 for Injection

Metastatic Solid Tumor

PHASE_1_2

Clinical Trials (1)

NCT05688280Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

Phase 1/2

Help build intelligence for Immunophotonics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage pipeline with IP-001 in Phase 1/2 and Phase 2/3 trials across colorectal cancer and solid tumors, offering exposure to novel vaccine modality development
Public company status provides transparency, equity upside potential, and established governance structures
Focused therapeutic strategy in high-value oncology and vaccine spaces with multi-indication potential

Watch Out For

Zero active job openings suggest minimal near-term hiring or potential organizational constraints
Early clinical stage (Phase 2/3 maximum) means extended runway before revenue inflection and financial risk
Sparse public data on financials, headcount, and recent milestones limits visibility into company stability and growth trajectory

Generated by Claude from Immunophotonics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

IP-001

Advanced Solid Tumors

PHASE_1_2

Clinical Trials (1)

NCT03993678Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.

Phase 1/2

IP-001

Colorectal Cancer

PHASE_1_2

1.0% IP-001 for Injection, a 10 mg/mL solution of IP-001 in water

Colorectal Cancer (CRC)

PHASE_2_3